194 related articles for article (PubMed ID: 27504877)
21. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
Meindl A; Hellebrand H; Wiek C; Erven V; Wappenschmidt B; Niederacher D; Freund M; Lichtner P; Hartmann L; Schaal H; Ramser J; Honisch E; Kubisch C; Wichmann HE; Kast K; Deissler H; Engel C; Müller-Myhsok B; Neveling K; Kiechle M; Mathew CG; Schindler D; Schmutzler RK; Hanenberg H
Nat Genet; 2010 May; 42(5):410-4. PubMed ID: 20400964
[TBL] [Abstract][Full Text] [Related]
22. Association between ERCC2 rs13181 polymorphism and ovarian cancer risk: an updated meta-analysis with 4024 subjects.
Li J; Pan L; Qin X; Chu H; Mu H; Wan G
Arch Gynecol Obstet; 2017 Sep; 296(3):551-558. PubMed ID: 28676967
[TBL] [Abstract][Full Text] [Related]
23. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer in an 18-year-old female: A fatal case report and literature review.
Jóźwik M; Posmyk R; Jóźwik M; Semczuk A; Gogiel-Shields M; Kuś-Słowińska M; Garbowicz M; Klukowski M; Wojciechowicz J
Cancer Biol Ther; 2018 Jul; 19(7):543-548. PubMed ID: 29723101
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
Kast K; Rhiem K; Wappenschmidt B; Hahnen E; Hauke J; Bluemcke B; Zarghooni V; Herold N; Ditsch N; Kiechle M; Braun M; Fischer C; Dikow N; Schott S; Rahner N; Niederacher D; Fehm T; Gehrig A; Mueller-Reible C; Arnold N; Maass N; Borck G; de Gregorio N; Scholz C; Auber B; Varon-Manteeva R; Speiser D; Horvath J; Lichey N; Wimberger P; Stark S; Faust U; Weber BH; Emons G; Zachariae S; Meindl A; Schmutzler RK; Engel C;
J Med Genet; 2016 Jul; 53(7):465-71. PubMed ID: 26928436
[TBL] [Abstract][Full Text] [Related]
26. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
[TBL] [Abstract][Full Text] [Related]
27. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene.
Fostira F; Kostantopoulou I; Apostolou P; Papamentzelopoulou MS; Papadimitriou C; Faliakou E; Christodoulou C; Boukovinas I; Razis E; Tryfonopoulos D; Barbounis V; Vagena A; Vlachos IS; Kalfakakou D; Fountzilas G; Yannoukakos D
J Med Genet; 2020 Jan; 57(1):53-61. PubMed ID: 31300551
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of germline mutations in breast cancer genes: RECQL.
Bowden AR; Tischkowitz M
Breast Cancer Res Treat; 2019 Apr; 174(3):553-560. PubMed ID: 30610487
[TBL] [Abstract][Full Text] [Related]
29. Association of R156R single nucleotide polymorphism of the ERCC2 gene with the susceptibility to ovarian cancer.
Romanowicz H; Michalska MM; Samulak D; Malinowski J; Szaflik T; Bieńkiewicz J; Smolarz B
Eur J Obstet Gynecol Reprod Biol; 2017 Jan; 208():36-40. PubMed ID: 27888704
[TBL] [Abstract][Full Text] [Related]
30. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
31. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
32. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
Rowley SM; Mascarenhas L; Devereux L; Li N; Amarasinghe KC; Zethoven M; Lee JEA; Lewis A; Morgan JA; Limb S; Young MA; James PA; Trainer AH; Campbell IG
Genet Med; 2019 Apr; 21(4):913-922. PubMed ID: 30254378
[TBL] [Abstract][Full Text] [Related]
33. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations.
Caligo MA; Ghimenti C; Cipollini G; Ricci S; Brunetti I; Marchetti V; Olsen R; Neuhausen S; Shattuck-Eidens D; Conte PF; Skolnick MH; Bevilacqua G
Oncogene; 1996 Oct; 13(7):1483-8. PubMed ID: 8875986
[TBL] [Abstract][Full Text] [Related]
35. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
Bergman A; Flodin A; Engwall Y; Arkblad EL; Berg K; Einbeigi Z; Martinsson T; Wahlström J; Karlsson P; Nordling M
Fam Cancer; 2005; 4(2):89-96. PubMed ID: 15951958
[TBL] [Abstract][Full Text] [Related]
36. RAD51C is a susceptibility gene for ovarian cancer.
Pelttari LM; Heikkinen T; Thompson D; Kallioniemi A; Schleutker J; Holli K; Blomqvist C; Aittomäki K; Bützow R; Nevanlinna H
Hum Mol Genet; 2011 Aug; 20(16):3278-88. PubMed ID: 21616938
[TBL] [Abstract][Full Text] [Related]
37. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
38. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
39. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
[TBL] [Abstract][Full Text] [Related]
40. Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families.
Bonache S; Gutierrez-Enriquez S; Tenés A; Masas M; Balmaña J; Diez O
Gynecol Oncol; 2013 Nov; 131(2):460-3. PubMed ID: 23911796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
